Latest News and Press Releases

Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...

New York, USA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The Global Point of Care Diagnostics Market to Progress at a CAGR of 7.99% by 2027, Assesses DelveInsight The point of care diagnostics market is...

Received frozen-formulation Allocetra™ IND clearance from The U.S. Food And Drug Administration (FDA) for treatment of patients with advanced solid tumorsThe protocol of the IND includes intravenous...

IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...

Multi-center trial of AllocetraTM in advanced solid tumor patientsAllocetraTM is administered to the patients either intravenously or locally, depending upon tumor locations, as both monotherapy and...

Nes-Ziona, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a...

New York, USA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The Global Sepsis Diagnostics Market to Register Growth at a CAGR of 9.60% by 2027 | DelveInsight The sepsis diagnostics market is expanding due to...

Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...

Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...

Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...